BioNTech SE (NASDAQ:BNTX) went up by 8.57% from its latest closing price compared to the recent 1-year high of $464.00. The company’s stock price has collected -0.80% of loss in the last five trading sessions. Barron’s reported 14 hours ago that Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases
Is It Worth Investing in BioNTech SE (NASDAQ :BNTX) Right Now?
BioNTech SE (NASDAQ:BNTX) scored a price-to-earnings ratio above its average ratio, recording 6.89 x from its present earnings ratio. Opinions of the stock are interesting as 5 analysts out of 16 who provided ratings for BioNTech SE declared the stock was a “buy,” while 0 rated the stock as “overweight,” 10 rated it as “hold,” and 1 as “sell.”
BNTX currently public float of 215.94M and currently shorts hold a 1.00% ratio of that float. Today, the average trading volume of BNTX was 3.23M shares.
BNTX’s Market Performance
BNTX stocks went down by -0.80% for the week, with a monthly drop of -19.07% and a quarterly performance of -5.36%, while its annual performance rate touched 111.20%. The volatility ratio for the week stands at 8.72% while the volatility levels for the past 30 days are set at 7.21% for BioNTech SE. The simple moving average for the period of the last 20 days is -9.41% for BNTX stocks with a simple moving average of -10.24% for the last 200 days.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Morgan Stanley repeating the rating for BNTX by listing it as a “Equal-Weight.” The predicted price for BNTX in the upcoming period, according to Morgan Stanley is $294 based on the research report published on December 16th of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $360. The rating they have provided for BNTX stocks is “Buy” according to the report published on November 10th, 2021.
Deutsche Bank gave a rating of “Hold” to BNTX, setting the target price at $250 in the report published on October 22nd of the previous year.
BNTX Trading at -15.94% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.43% of loss for the given period.
Volatility was left at 7.21%, however, over the last 30 days, the volatility rate increased by 8.72%, as shares sank -10.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.01% lower at present.
During the last 5 trading sessions, BNTX fell by -0.80%, which changed the moving average for the period of 200-days by +140.18% in comparison to the 20-day moving average, which settled at $252.50. In addition, BioNTech SE saw -10.78% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNTX
Equity return is now at value 165.70, with 100.20 for asset returns.